426 related articles for article (PubMed ID: 23147664)
41. Goals and targets for personalized therapy for HCC.
Couri T; Pillai A
Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
[TBL] [Abstract][Full Text] [Related]
42. Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know.
Kim YH; Kim DY
Oncology; 2013; 84 Suppl 1():34-9. PubMed ID: 23428856
[TBL] [Abstract][Full Text] [Related]
43. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
Feng X; Xu R; Du X; Dou K; Qin X; Xu J; Jia W; Wang Z; Zhao H; Yang S; Guo C; Liu T; Ma K
Am J Gastroenterol; 2014 Dec; 109(12):1891-9. PubMed ID: 25403366
[TBL] [Abstract][Full Text] [Related]
44. Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Rognoni C; Ciani O; Sommariva S; Tarricone R
Value Health; 2017 Mar; 20(3):336-344. PubMed ID: 28292478
[TBL] [Abstract][Full Text] [Related]
45. Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review.
Han K; Kim JH; Ko GY; Gwon DI; Sung KB
World J Gastroenterol; 2016 Jan; 22(1):407-16. PubMed ID: 26755886
[TBL] [Abstract][Full Text] [Related]
46. Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma?
Jiang W; Zeng ZC
Oncology; 2013; 84 Suppl 1():69-74. PubMed ID: 23428862
[TBL] [Abstract][Full Text] [Related]
47. Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment.
Jun CH; Yoon JH; Cho E; Shin SS; Cho SB; Kim HJ; Park CH; Kim HS; Choi SK; Rew JS
Medicine (Baltimore); 2017 Apr; 96(17):e6745. PubMed ID: 28445298
[TBL] [Abstract][Full Text] [Related]
48. Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.
Park JG; Park SY; Lee HW
World J Gastroenterol; 2015 Feb; 21(8):2568-72. PubMed ID: 25741170
[TBL] [Abstract][Full Text] [Related]
49. [Complete Surgical Resection of a Huge Hepatocellular Carcinoma Invading the Diaphragm and Lung after Transcatheter Arterial Chemoembolization (TACE) and Sorafenib--A Case Report].
Mukai Y; Wada H; Eguchi H; Tomokuni A; Tomimaru Y; Asaoka T; Kawamoto K; Marubashi S; Umeshita K; Doki Y; Mori M; Nagano H
Gan To Kagaku Ryoho; 2015 Nov; 42(12):1638-40. PubMed ID: 26805122
[TBL] [Abstract][Full Text] [Related]
50. [Two Patients with Recurrence of Hepatocellular Carcinoma after Liver Resection Who Achieved Long-Term Stable Disease with Small Doses of Sorafenib Therapy].
Kitade H; Yanagida H; Yokoigawa N; Yamada M; Hijikawa T; Kaibori M; Matsui K; Ishizaki M; Yoshioka K; Kon M
Gan To Kagaku Ryoho; 2015 Jul; 42(7):863-5. PubMed ID: 26197751
[TBL] [Abstract][Full Text] [Related]
51. Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice.
Cabibbo G; Petta S; Maida M; Cammà C
Dig Dis; 2015 Sep; 33(5):668-74. PubMed ID: 26398633
[TBL] [Abstract][Full Text] [Related]
52. [Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy].
Watanabe Y; Nakaba H; Taniguchi E; Kikkawa H; Tamagawa H; Sasaki M; Kitayama T; Doi Y; Oguchi Y
Gan To Kagaku Ryoho; 2014 Nov; 41(12):2110-2. PubMed ID: 25731439
[TBL] [Abstract][Full Text] [Related]
53. Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.
Meng XC; Chen BH; Huang JJ; Huang WS; Cai MY; Zhou JW; Guo YJ; Zhu KS
World J Gastroenterol; 2018 Jan; 24(4):484-493. PubMed ID: 29398869
[TBL] [Abstract][Full Text] [Related]
54. An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis.
Salhab M; Canelo R
J Cancer Res Ther; 2011; 7(4):463-75. PubMed ID: 22269411
[TBL] [Abstract][Full Text] [Related]
55. Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review.
Golse N; Radenne S; Rode A; Ducerf C; Mabrut JY; Merle P
Exp Clin Transplant; 2018 Apr; 16(2):227-236. PubMed ID: 27212671
[TBL] [Abstract][Full Text] [Related]
56. Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
Zhou L; Li J; Ai DL; Fu JL; Peng XM; Zhang LZ; Wang JY; Zhao Y; Yang B; Yu Q; Liu CZ; Wang HM
Jpn J Clin Oncol; 2014 Aug; 44(8):711-7. PubMed ID: 24855686
[TBL] [Abstract][Full Text] [Related]
57. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
Gish RG; Finn RS; Marrero JA
Clin Adv Hematol Oncol; 2013 Apr; 11 Suppl 5():1-22; quiz 2 p following p22. PubMed ID: 23881427
[TBL] [Abstract][Full Text] [Related]
58. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.
Villanueva A; Minguez B; Forner A; Reig M; Llovet JM
Annu Rev Med; 2010; 61():317-28. PubMed ID: 20059340
[TBL] [Abstract][Full Text] [Related]
59. Treatment of hepatocellular carcinoma: beyond international guidelines.
Colombo M; Sangiovanni A
Liver Int; 2015 Jan; 35 Suppl 1():129-38. PubMed ID: 25529098
[TBL] [Abstract][Full Text] [Related]
60. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Bai W; Wang YJ; Zhao Y; Qi XS; Yin ZX; He CY; Li RJ; Wu KC; Xia JL; Fan DM; Han GH
J Dig Dis; 2013 Apr; 14(4):181-90. PubMed ID: 23324079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
